Diagnostic and Therapeutic Endoscopy / 2013 / Article / Tab 2 / Review Article
Peroral Endoscopic Myotomy for the Treatment of Achalasia: An Analysis Table 2 Adverse events associated with POEM.
Authors Patients (
) Adverse events*,
Additional treatment Inoue et al. [13 ] 17 1 pneumoperitoneum Veress needle Swanström et al. [14 ] 5 2 small perforations in gastric cardia 3 capnoperitoneum Endoscopic clips Veress needle von Renteln et al. [15 ] 16 6 minor cutaneous emphysema 8 capnoperitoneum treated with Veress needle 1 small perforation at GEJ, treated with endoscopic clips Veress needle Endoscopic clips Costamagna et al. [16 ] 11 2 small perforations at junctional flap Asymptomatic pneumomediastinum in all patients 2 transient cervical emphysema Endoscopic clips Chiu et al. [17 ] 16 1 aspiration pneumonia 2 transient cervical emphysema Hospital admission and monitoring Hungness et al. [21 ] 18 7 capnoperitoneum 1 contained perforation at the EGJ Veress needle Ren et al. [25 ] 119 66 subcutaneous emphysema 30 pneumothorax 35 mediastinal emphysema 1 delayed hemorrhage 58 pleural effusions 59 inflammations/atelectases of the lungs 47 aeroperitonea Zhou et al. [24 ] 12 1 small perforation at GEJ, treated with endoscopic clips 3 capnoperitoneum, one treated with Veress needle 4 pneumothorax, one treated with thoracic tube 4 mediastinal emphysema 2 subcutaneous emphysema Endoscopic clips Veress needle Thoracic tube Verlaan et al. [18 ] 10 No complications reported None Minami et al. [20 ] 28 1 perforation at GEJ, treated with endoscopic clips 2 postoperative bleedings Endoscopic clips Lee et al. [19 ] 13 No complications reported None Von Renteln et al. [22 ] 70 3 clip dislocation at mucosal closure 1 perforation at mucosal entry site 3 mucosal injuries 1 bleeding requiring intervention 1 cap detached in submucosal tunnel 1 delayed bleeding (hematoma) Endoscopic reclipping Endoscopic clips Endoscopic clips Endoscopic hemostasis Endoscopic removal Hospital admission and monitoring
includes all reported outcomes, including nonclinically significant and asymptomatic adverse events.